Clendening et al. [7] showed that HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) and other genes encoding enzymes or regulatory proteins of the mevalonate (MVA) pathway exhibit aberrantly high expression in breast cancers and overexpression of HMGCR or its novel transcript variant lacking exon 13 promoted cellular transformation indicating that HMGCR represents a metabolic oncogene [7]. The gene discussed is HMGCR; the disease is breast carcinoma.